JP2013545748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545748A5 JP2013545748A5 JP2013538866A JP2013538866A JP2013545748A5 JP 2013545748 A5 JP2013545748 A5 JP 2013545748A5 JP 2013538866 A JP2013538866 A JP 2013538866A JP 2013538866 A JP2013538866 A JP 2013538866A JP 2013545748 A5 JP2013545748 A5 JP 2013545748A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- diketopiperazine
- fumaryl
- aminobutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims description 11
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- -1 aliphatic amino acids Chemical class 0.000 claims description 7
- 229960003708 sumatriptan Drugs 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 229960000658 sumatriptan succinate Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical group CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 6
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000952 serotonin receptor agonist Substances 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 229960000425 rizatriptan Drugs 0.000 claims 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N Rizatriptan benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.C1=C2C(CC[NH+](C)C)=CNC2=CC=C1CN1C=NC=N1 JPRXYLQNJJVCMZ-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 229960002133 almotriptan Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002472 eletriptan Drugs 0.000 claims 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 1
- 229960002284 frovatriptan Drugs 0.000 claims 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960005254 naratriptan Drugs 0.000 claims 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960004789 rizatriptan benzoate Drugs 0.000 claims 1
- 208000018316 severe headache Diseases 0.000 claims 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 229960001360 zolmitriptan Drugs 0.000 claims 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 1
- 239000012488 sample solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41177510P | 2010-11-09 | 2010-11-09 | |
| US61/411,775 | 2010-11-09 | ||
| US41233910P | 2010-11-10 | 2010-11-10 | |
| US61/412,339 | 2010-11-10 | ||
| PCT/US2011/060057 WO2012064892A1 (en) | 2010-11-09 | 2011-11-09 | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021017A Division JP6458064B2 (ja) | 2010-11-09 | 2017-02-08 | ジケトピペラジンを含む治療のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545748A JP2013545748A (ja) | 2013-12-26 |
| JP2013545748A5 true JP2013545748A5 (enExample) | 2016-04-07 |
| JP6092113B2 JP6092113B2 (ja) | 2017-03-08 |
Family
ID=45048258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538866A Active JP6092113B2 (ja) | 2010-11-09 | 2011-11-09 | セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 |
| JP2017021017A Active JP6458064B2 (ja) | 2010-11-09 | 2017-02-08 | ジケトピペラジンを含む治療のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021017A Active JP6458064B2 (ja) | 2010-11-09 | 2017-02-08 | ジケトピペラジンを含む治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP3536368B1 (enExample) |
| JP (2) | JP6092113B2 (enExample) |
| KR (1) | KR101931392B1 (enExample) |
| CN (2) | CN107854454A (enExample) |
| AU (1) | AU2011326529B2 (enExample) |
| BR (1) | BR112013011549B1 (enExample) |
| CA (1) | CA2817337C (enExample) |
| ES (1) | ES2732818T3 (enExample) |
| MX (2) | MX376862B (enExample) |
| WO (1) | WO2012064892A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4681231B2 (ja) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | 吸入装置 |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| CN103599155B (zh) * | 2013-11-27 | 2015-12-02 | 广州安健实业发展有限公司 | 治疗偏头痛的方法 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| EP3288591A1 (en) * | 2015-05-01 | 2018-03-07 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| EP3316865A4 (en) | 2015-07-02 | 2019-01-23 | Civitas Therapeutics, Inc. | TRIPTAN POWDER FOR PULMONARY ADMINISTRATION |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| GB201709459D0 (en) * | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US11135379B2 (en) | 2019-02-15 | 2021-10-05 | Bn Intellectual Properties, Inc. | Method of delivering pharmaceutical products |
| MD3989962T2 (ro) | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
| US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
| CN1176649C (zh) * | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) * | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| KR20100090692A (ko) * | 2007-10-24 | 2010-08-16 | 맨카인드 코포레이션 | 활성제의 전달 |
| KR101736502B1 (ko) * | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| US20110077272A1 (en) * | 2008-02-01 | 2011-03-31 | Vectura Limited | Pulmonary formulations of triptans |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
-
2011
- 2011-11-09 MX MX2016008519A patent/MX376862B/es unknown
- 2011-11-09 EP EP19168470.3A patent/EP3536368B1/en active Active
- 2011-11-09 KR KR1020137014686A patent/KR101931392B1/ko active Active
- 2011-11-09 MX MX2013005294A patent/MX340112B/es active IP Right Grant
- 2011-11-09 EP EP11788696.0A patent/EP2637657B1/en active Active
- 2011-11-09 JP JP2013538866A patent/JP6092113B2/ja active Active
- 2011-11-09 CN CN201710887079.8A patent/CN107854454A/zh active Pending
- 2011-11-09 ES ES11788696T patent/ES2732818T3/es active Active
- 2011-11-09 WO PCT/US2011/060057 patent/WO2012064892A1/en not_active Ceased
- 2011-11-09 CA CA2817337A patent/CA2817337C/en active Active
- 2011-11-09 BR BR112013011549-1A patent/BR112013011549B1/pt active IP Right Grant
- 2011-11-09 AU AU2011326529A patent/AU2011326529B2/en active Active
- 2011-11-09 CN CN2011800540606A patent/CN103200940A/zh active Pending
-
2017
- 2017-02-08 JP JP2017021017A patent/JP6458064B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6458064B2 (ja) | ジケトピペラジンを含む治療のための組成物 | |
| JP6165300B2 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| Leung et al. | Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections: Leung et al. | |
| JP5788806B2 (ja) | 薬物送達剤用置換ジケトピペラジン及びその塩、これらを含む治療用組成物、微粒子組成物及び乾燥粉末組成物、並びに、その調整方法 | |
| CN108033921B (zh) | 3,5-二氨基-6-氯-n-(n-(4-(4-(2-(己基(2,3,4,5,6-五羟基己基)氨基)乙氧基)苯基)丁基)甲脒基)吡嗪-2-甲酰胺 | |
| JP2022017283A (ja) | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 | |
| ES2647080T3 (es) | Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo | |
| CN105792847B (zh) | 急性骨髓性白血病(aml)的新型组合治疗 | |
| JP2014530914A5 (ja) | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム | |
| RU2463051C2 (ru) | Фармацевтическая композиция, содержащая производное пиразина, и способ применения производного пиразина в комбинации | |
| JP2014515356A5 (enExample) | ||
| AU2017286864A1 (en) | Nicotine particles and compositions | |
| CN106456707B (zh) | 干粉肽药剂 | |
| CN104955812B (zh) | 经芳烷基和芳氧基烷基取代的上皮钠通道阻断化合物 | |
| CA3217735A1 (en) | Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor | |
| US20060039985A1 (en) | Methotrexate compositions | |
| US20220378727A1 (en) | Dry powder formulations of tamibarotene for pulmonary and intranasal delivery | |
| US8193152B2 (en) | Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds | |
| CN104784159A (zh) | 氨曲南粉雾剂的制备方法 | |
| AU2015249177B2 (en) | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines | |
| KR20180052566A (ko) | 폐 전달용 트립탄 분말 | |
| HK40014359B (en) | Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines | |
| CN108307631A (zh) | 用于预防和/或治疗化疗的不良副作用的可乐定和/或可乐定衍生物 | |
| HK1189503A (en) | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |